<?xml version="1.0" encoding="UTF-8"?>
<p id="Par13">M2 of IAV (AM2) is a type III integral membrane protein, consisting of an N-terminal extracellular region (M2e), transmembrane region, and C-terminal cytoplasmic tail region (Fig.Â 
 <xref rid="Fig1" ref-type="fig">1</xref>B) (Tobler 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR97">1999</xref>). The M2e is a 24-residue peptide and is highly conserved among different IAV subtypes (Deng 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR21">2015</xref>). Although the natural M2e has low immunogenicity and abundance, a M2e-specific and protective monoclonal antibody 14C2 has been isolated early (Zebedee and Lamb 
 <xref ref-type="bibr" rid="CR118">1989</xref>; Treanor 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR98">1990</xref>). Therefore this region has since been extensively evaluated as a promising immunogen for universal influenza vaccines (Farahmand 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR33">2019</xref>; Yao 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR116">2019</xref>).
</p>
